Radically extended
healthspan for all
38+ million lives and counting
Healthspan is the period of life spent in good health, generally free from disease and disability.
Early stage healthtech venture capital fund investing in impactful health technology startups globally.
Our Mission
Healthtech investment is the key to extending healthspan for all.
Traditional healthcare is slow and ineffective. To radically extend healthspan for all, we believe healthcare needs to be exponentially more efficient and effective. Healthtech is leading this change.
Healthtech leverages technology to amplify the current health system. It connects and extends traditional health sectors with adjacent non-health sectors that easily reach billions.
Why Founders Choose Us
More Than Capital. A Partner.
We don't just write cheques. We provide the clinical, regulatory, and commercial expertise needed to navigate the complex healthcare landscape.
Specialists, Not Generalists
We are clinicians, scientists, and operators. We understand the science, the regulatory pathways (FDA/CE), and the clinical workflows required for adoption.
Global Commercialisation
Healthcare is local, but innovation is global. We bridge Asian, European, and US markets, helping portfolio companies expand internationally from day one.
Hands-On Validation
We help structure clinical trials and pilot programs through our network of hospital partners. We de-risk the path from bench to bedside.
Our partners have led digital transformations at top-tier firms and founded successful healthtech startups. We've sat in your seat.
Changemakers. Not just investors.
We seek and support visionary, passionate, and persistent founders who are creating transformative healthtech companies today that shape our vision of tomorrow.
Active Expertise
Experienced healthtech operators that actively partner with founders crossing the chasm from early to growth stage.
Global Ecosystem
Access to Verge's global network of leading companies, investors, and institutions to help your company scale.
Portfolio Synergies
Collaboration with our extended portfolio on R&D, commercial distribution, and clinical trials.
Investment Scope
Where we invest in global healthtech.
We invest in & help scale:
Technologies that solve large unmet needs in health and platforms that can reach millions.
AI and Data Analytics
Solutions that use artificial intelligence and/or data analysis techniques to extract actionable and valuable insights and patterns within healthcare data.
Next Gen Diagnostics
Advanced diagnostic tools incorporating cutting-edge detection technologies, algorithms and/or novel biomarkers, to diagnose and/or monitor diseases earlier.
Breakthrough Smart Devices
Highly innovative wearable or portable devices that incorporate smart technologies to monitor, diagnose, or treat health conditions.
Digital Health Platforms
Online platforms that facilitate various health services such as telemedicine, remote patient monitoring, chronic disease management, and patient engagement.
Digital Therapeutics
Digital systems or software used as therapeutic interventions for treating, managing, or preventing a specific health condition.
Healthcare SaaS
Software-as-a-Service platforms specifically designed for healthcare that do not directly face patients, such as EHR, billing, and inventory management.
Global Footprint
Global healthtech investment has no borders.
38,340,535 lives impacted across our global portfolio.
36
Companies
50
Countries
22
LMIC Markets
Portfolio
Healthtech startups backed by Verge.

Arogga
Vertically integrated digital pharmacy in Bangladesh with proprietary fulfilment infrastructure delivering authentic medications

Bot MD
Chat-first automation platform that embeds AI agents into messaging apps to digitise patient engagement workflows

BrainCapture
Low-cost, high quality, smartphone pairable EEG amplifier with a novel cap that allows for remote neurology diagnostics

CareLoop Health
Predictive digital therapeutics for people living with serious mental illness, starting with psychosis
ChestPal
The world’s most affordable and intelligent digital stethoscope for lung sounds (and soon heart)

CuboAi
Proactive AI for your baby's sleep, safety, health, and memories
Insights
Latest news & updates
Verge named MedTech Venture Capital of the Year at MedTech World Asia Awards 2026
Verge HealthTech Fund was named MedTech Venture Capital of the Year at the MedTech World Asia Awards 2026 in Hong Kong. This recognition involved a rigorous selection process of over 5,500 public votes and a final expert committee review.
ThinkMD.ai Surpasses 32,000 Clinical Risk Assessments in Somalia
ThinkMD.ai has surpassed 32,000 clinical risk assessments since launching in South West State, Somalia, in January 2026. Patient encounters have increased nearly six-fold since the first month of operations, reflecting adoption among health workers for routine care. To date, the platform has facilitated over 2,300 patient encounters across 20 clinical facilities, with pediatric cases comprising nearly half of these interactions. The platform currently supports various clinical areas, including antenatal, newborn, postnatal, youth, and adult care. Developed in partnership with the Ministry of Health-Somalia MoH and Cleanport, ThinkMD.ai enables health workers to identify danger signs, support consistent care protocols, and provide Ministry of Health officials with real-time data across monitored facilities.
Dexcom and Health2Sync expand diabetes care partnership in APAC
Dexcom and Health2Sync have announced the expansion of their strategic partnership to Australia and Singapore, building on their existing collaboration in Japan. The initiative aims to enhance the connected diabetes care ecosystem across the APAC region by integrating Dexcom's Continuous Glucose Monitoring (CGM) data with Health2Sync's digital health platform. This integration is designed to provide a more seamless experience for both healthcare providers and patients living with diabetes, offering meaningful health insights. The companies expect the new integration to go live in the coming months. Dexcom reminds users to always read the label and follow the directions for use, noting that their CGM systems are indicated for the management of type 1, type 2, and gestational diabetes in people aged 2 years and older where self-monitoring of blood glucose is indicated.
Our Team
Seasoned investors.
Former operators.
Ready to build
the future?
We are looking for visionary founders solving the hardest problems in healthcare. If that's you, we want to hear from you.